NK1.1+ cells and CD8+ T cells mediate the antitumor activity of CL-IB-MECA in a mouse melanoma model

Neoplasia

Volumn 13, Issue 4, 2011, Pages 365-373

  Morello, Silvana ^a   Sorrentino, Rosalinda ^a   Montinaro, Antonella ^a   Luciano, Antonio ^b   Maiolino, Piera ^b   Ngkelo, Anta ^c   Arra, Claudio ^b   Adcock, Ian M ^c   Pinto, Aldo ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE A3 RECEPTOR AGONIST; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERLEUKIN 12P40; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFECT; FEMALE; LYMPHOCYTE COUNT; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH;

EID: 79953715698     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101628     Document Type: Article

References (37)

1. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, and Chanmugam A (2006). Cutaneous malignant melanoma. Mayo Clin Proc 81, 500-507.
2. Soengas MS and Lowe SW (2003). Apoptosis and melanoma chemoresistance. Oncogene 22, 3138-3152.
3. Kirwood JM, Moschos S, and Wang W (2006). Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines and combinations. Clin Cancer Res 12, 2331s-2336s.
4. Drake CG, Jaffee E, and Pardoll DM (2006). Mechanisms of immune evasion by tumours. Adv Immunol 90, 51-81.
5. Blay J, White TD, and Hoskin DW (1997). The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 57, 2602-2605.
6. Ohta A and Sitkovsky M (2001). Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414, 916-920.
7. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MKK, Huang X, Caldwell S, Liu K, Smith P, et al. (2006). A2A adenosine receptor protects tumours from antitumour T cells. Proc Natl Acad Sci USA 103, 13132-13137.
8. Panther E, Corinti S, Idzko M, Herouy Y, Napp M, la Sala A, Girolomoni G, and Norgauer J (2003). Adenosine affects expression of membrane molecule, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood 101, 3985-3990.
9. Sitkovsky M and Ohta A (2005). The "danger" sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol 26, 299-304.
10. 8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signalling. Cancer Res 67, 5949-5956.
11. Zarek PE, Huang CT, Lutz ER, Kowalski J, Horton MR, Linden J, Drake CG, and Powell JD (2008). A2A receptor signalling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111, 251-259.
12. Haskó G, Linden J, Cronstein B, and Pacher P (2008). Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7(9), 759-770.
13. Fishman P, Bar-Yehuda MS, Synowitz M, Powell JP, Klotz KN, Gessi S, and Borea PA (2009). Adenosine receptors and cancer. In Adenosine Receptors in Health and Disease. Handbook of Experimental Pharmacology. CN Wilson and SJ Mustafa (Eds). Springer-Verlag, Berlin, Germany. pp. 399-441.
14. Morello S, Petrella A, Festa M, Popolo A, Monaco M, Vuttariello E, Chiappetta G, Parente L, and Pinto A (2008). Cl-IB-MECA inhibits human thyroid cancer cell proliferation independently of A3 adenosine receptor activation. Cancer Biol Ther 7, 278-284.
15. Morello S, Sorrentino R, Porta A, Forte G, Popolo A, Petrella A, and Pinto A (2009). Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-κB signalling pathway in thyroid cancer cells. J Cell Physiol 221, 378-386.
16. Harish A, Hohana G, Fishman P, Arnon O, and Bar-Yehuda S (2003). A3 adenosine receptor agonist potentiates natural killer cell activity. Int J Oncol 23, 1245-1249.
17. Ohana G, Bar-Yehuda S, Arich A, Madi L, Dreznick Z, Silberman D, Slosman G, Volfsson-Rath L, and Fishman P (2003). Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101. Br J Cancer 89, 1552-1558.
18. 8+ T cells. J Immunol 181, 6148-6157.
19. Mita AC, Mita MM, Nawrocki ST, and Giles FJ (2008). Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14, 5000-5005.
20. Zhao TC and Kukreja RC (2002). Late preconditioning elicited by activation of adenosine A (3) receptor in heart: role of NF-κB, iNOS and mitochondrial K (ATP) channel. J Mol Cell Cardiol 34(3), 263-277.
21. Suk K, Chang I, Kim YH, Kim S, Kim JY, Kim H, and Lee MS (2001). Interferon gamma (IFNγ) and tumor necrosis factor α synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFNγ inhibits cytoprotective NF-κB through STAT1/IRF-1 pathways. J Biol Chem 276, 13153-13159.
22. Dunn GP, Koebel CM, and Schreiber RD (2006). Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6, 836-848.
23. Loza MJ, Zamai L, Azzoni L, Rosati E, and Perussia B (2002). Expression of type 1 (interferon γ) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. Blood 99, 1273-1281.
24. Neurath MF, Finotto S, and Glimcher IH (2002). The role of TH1/TH2 polarization in mucosal immunity. Nat Med 8, 567-573.
25. Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, and Glimcher LH (2002). Distinct effects on T-bet in TH1 lineage commitment and IFN-γ production in CD4 and CD8 T cells. Science 295, 338-342.
26. Palucka K and Banchereau J (1999). Linking innate and adaptive immunity. Nat Med 5, 868-870.
27. 8+ T cell- mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer 109, 499-506.
28. Mellman I and Steinman RM (2001). Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255-258.
29. Solana R, Casado JG, Delgado E, DelaRosa O, Marín J, Durán E, Pawelec G, and Tarazona R (2007). Lymphocyte activation in response to melanoma: interaction of NK-associated receptors and their ligands. Cancer Immunol Immunother 56, 101-109.
30. Banchereau J and Steinman RM (1998). Dendritic cells and the control of immunity. Nature 392, 245-252.
31. Burnstock G (1997). The past, present and future of purine nucleotides as signaling molecules. Neuropharmacology 36, 1127-1139.
32. Klinger M, Freissmuth M, and Nanoff C (2002). Adenosine receptors: G protein- mediated signalling and the role of accessory proteins. Cell Signal 14, 99-108.
33. Lukashev D, Ohta A, and Sitovsky M(2007).Hypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues. Cancer Metastasis Rev 26, 273-279.
34. El Marsafy S, Bagot M, Bensussan A, and Mauviel A (2008). Dendritic cells in the skin-potential use for melanoma treatment. Pigment Cell Melanoma Res 22, 30-41.
35. Hayday A and Tigelaar R (2003). Immunoregulation in the tissues by γδ T cells. Nat Rev Immunol 3, 233-242.
36. Reis e Sousa C (2004). Activation of dendritic cells: translating innate into adaptive immunity. Curr Opin Immunol 16, 21-25.
37. Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, and Jacobson MA (2000). Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem 275(6), 4429-4434.